Selective Amylin Receptor Agonist

    Eloralintide

    LY3841136

    Eloralintide is a next-generation selective long-acting amylin receptor agonist. Engineered for amylin receptor selectivity (unlike the dual amylin/calcitonin binding of Cagrilintide), it is one of the most closely watched investigational compounds in obesity and metabolic research today, with Phase 2 data now published and the ENLIGHTEN Phase 3 programme underway.

    Eloralintide 10mg single research vial

    Eloralintide Single vial · Incretin / GLP-1

    Strength

    Volume pricing

    Any mix of Express vials counts. Not combined with discount codes.

    Add 1 more to unlock 5% off

    Your basket is empty

    With this one in, 1 vial more of anything and the whole basket is 5% off.

    For laboratory research use only. Not for human or veterinary use.

    5.018 verified customer reviewsRead all reviews

    What is Eloralintide (LY3841136)?

    Eloralintide, development code LY3841136, is a synthetic peptide engineered as a selective long-acting amylin receptor agonist. Amylin is a 37-amino-acid peptide co-secreted with insulin from pancreatic beta-cells, and its receptor system plays a distinct role in appetite regulation, gastric emptying, and glucagon suppression alongside the incretin family compounds like Semaglutide and Tirzepatide.

    Unlike Cagrilintide, which engages both the amylin and calcitonin receptors, Eloralintide is designed for amylin receptor selectivity. The rationale is to reduce off-target signalling and improve gastrointestinal tolerability compared with dual-receptor amylin analogues. This design choice makes Eloralintide a unique research tool for isolating the pharmacology of the amylin arm.

    Phase 2 data for Eloralintide was published in 2026, with the ENLIGHTEN Phase 3 programme now underway. See the original literature via Google Scholar and ClinicalTrials.gov. Eloralintide remains investigational and is not licensed for human use.

    Selective Amylin Mechanism of Action

    Native amylin signals through a heterodimeric receptor complex formed when the calcitonin receptor pairs with a receptor activity-modifying protein (RAMP1, RAMP2 or RAMP3). Eloralintide's design targets this amylin-selective heterodimer preferentially over the calcitonin receptor alone, which is the source of its selectivity profile.

    Appetite & Satiety

    Amylin acts on hypothalamic and area postrema circuits to reduce food intake, a pathway complementary to but mechanistically distinct from GLP-1 mediated satiety.

    Gastric Emptying

    Amylin receptor activation slows gastric emptying, extending postprandial satiety without the same magnitude of GI adverse events seen with incretin monotherapy.

    Glucagon Suppression

    Postprandial glucagon suppression contributes to improved glucose excursions, distinct from insulin-mediated pathways.

    For background on amylin receptor pharmacology, see the Wikipedia amylin overview or the PubMed literature on amylin receptor agonists.

    Research Applications

    Eloralintide is used in laboratory research settings to investigate a range of pathways specific to selective amylin agonism:

    • Amylin Receptor Selectivity: Binding kinetics at AMY1, AMY2 and AMY3 receptor subtypes versus the calcitonin receptor, using radioligand displacement and cAMP accumulation assays.
    • Combination Pharmacology: Co-administration models with dual incretin agonists such as Tirzepatide, mirroring the ENLIGHTEN combination trial design.
    • Comparative Studies: Head-to-head profiling against Cagrilintide to isolate the contribution of calcitonin receptor engagement.
    • Appetite & Feeding Models: Characterising acute and chronic effects on food intake in preclinical models.
    • GI Tolerability Profiling: Comparing nausea and gastric-emptying markers versus GLP-1 monotherapy at matched body-weight reduction timepoints.

    Storage, Handling and Reconstitution

    Long-Term Storage

    Store unreconstituted vials at -20 to -80C. Peptide is stable for 24 months or longer. Keep sealed, protected from light and moisture.

    Short-Term Storage

    Unreconstituted vials may be stored at 2 to 8C for up to 90 days without significant degradation.

    Reconstitution

    Reconstitute with bacteriostatic water. Add solvent slowly along the vial wall. Do not vortex; swirl gently until fully dissolved.

    Post-Reconstitution

    Store reconstituted peptide at 2 to 8C, use within 28 days. Aliquot for freezing; avoid repeated freeze-thaw cycles.

    Research on Eloralintide

    What net peptide content meansBrowse the research library

    Frequently Asked Questions About Eloralintide

    What is Eloralintide?▼
    Eloralintide (LY3841136) is a selective long-acting amylin receptor agonist. Unlike Cagrilintide, which activates both amylin and calcitonin receptors, Eloralintide is engineered for amylin receptor selectivity. It is currently investigational and supplied strictly as a laboratory research reference material.
    How does Eloralintide differ from Cagrilintide?▼
    Both belong to the amylin class, but Eloralintide is engineered for amylin receptor selectivity, while Cagrilintide is a dual amylin and calcitonin receptor agonist. The published Phase 2 Eloralintide data suggests a distinct gastrointestinal tolerability profile compared with dual-receptor amylin analogues.
    What Phase 2 data has been published for Eloralintide?▼
    The 48-week, double-blind, placebo-controlled Phase 2 trial in adults with overweight or obesity reported dose-dependent weight reduction with weekly subcutaneous administration. A separate combination arm evaluated Eloralintide co-administered with Tirzepatide under trial registration NCT06916065. The ENLIGHTEN Phase 3 programme is the successor.
    What purity is Peptx Eloralintide?▼
    All Peptx Eloralintide is typically 99%+ purity (HPLC), with a guaranteed minimum stated per compound, verified by HPLC and Mass Spectrometry. Suppliers are cross-referenced against independent lab testing and live community feedback. Buyers may independently retest any batch through an accredited third-party lab.
    Is Eloralintide available for purchase?▼
    Peptx is accepting pre-orders for Eloralintide 10mg lyophilised vials. Stock allocation and dispatch begin once the first production batch clears QC. Register on the shop page to be notified when stock lands.
    How should Eloralintide be stored?▼
    Unreconstituted Eloralintide should be stored at -20C for long-term storage or 2 to 8C for short-term use. Once reconstituted with bacteriostatic water, store at 2 to 8C and use within 28 days. Protect from light and avoid repeated freeze-thaw cycles.

    Related Research Peptides

    Researchers profiling Eloralintide often compare with these compounds:

    Amylin + Calcitonin

    Cagrilintide

    The closest analogue, dual-receptor amylin/calcitonin agonist with the most mature combination dataset (CagriSema).

    GLP-1 / GIP Dual

    Tirzepatide

    The dual incretin combination partner used in the Eloralintide plus Tirzepatide ENLIGHTEN trial arm.

    GLP-1/GIP/GCGR Triple

    Retatrutide

    The leading non-amylin competitor for next-generation obesity research.

    Eloralintide vs CagrilintideEloralintide vs TirzepatideEloralintide vs RetatrutideEloralintide vs SemaglutidePetrelintide vs EloralintideAll GLP peptides

    Eloralintide (LY3841136) is sold by Peptx strictly for laboratory and research purposes only. It is not intended for human consumption, veterinary use, food additive, or cosmetic applications. By purchasing this product, the buyer confirms it will be used exclusively for qualified scientific research. Peptx makes no claims regarding therapeutic efficacy.